The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol cover the XVIII International AIDS Conference (AIDS 2010)
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Clinical Highlights From AIDS 2010: An Interview With Joel Gallant, M.D.

August 23, 2010

As AIDS 2010 drew to a close, Fred Schaich of the International Foundation for Alternative Research in AIDS sat down with one of the U.S.'s top HIV/AIDS clinicians, Joel Gallant, M.D., for his take on the clinical highlights from the conference -- that is, the developments that are most likely to have an impact on HIV treatment in the future.

During their 21-minute chat, Gallant and Schaich touched on a number of key studies presented at AIDS 2010, including:

  • Thoughts on the CAPRISA microbicide trial and the future of antiretroviral-based prevention methods. (Begins at 1:24)
  • The latest in the "when to start" debate regarding antiretroviral therapy, including new International AIDS Society-USA guidelines and results from the CASCADE study. (Begins at 3:24)
  • Mixed news on TMC278 (rilpivirine), an NNRTI in development, from the ECHO and THRIVE studies. (Begins at 5:35)
  • Encouraging results on the pipeline integrase inhibitor S/GSK1349572 (from the SPRING-1 and VIKING studies), tempered by concerns over the impact of raltegravir resistance. (Begins at 7:24)
  • Research on a once-daily, extended-release form of Viramune (nevirapine), which found that the dose appears effective but that short-term side effects, such as acute skin complications, may be a concern. (Begins at 9:37)
  • Studies on "nuke-sparing" (i.e., NRTI-free) options: Reyataz (atazanavir) plus Isentress (raltegravir) in the SPARTAN study (which didn't look so great), and Kaletra (lopinavir/ritonavir) plus raltegravir in the PROGRESS study (which looked pretty good). (Begins at 11:14)
  • A discussion on the potential benefits and risks of "simplifying" treatment (by reducing the number of antiretrovirals in a successful regimen), including a look at the SPIRAL study. (Begins at 12:43)
  • A brief look at Selzentry (maraviroc) as first-line treatment, which appeared promising in a phase 2 study. (Begins at 16:07)
  • An assessment of how HIV treatment options may evolve over the years to come -- for better or for worse. (Begins at 16:24)

You can watch the full interview below; video production is courtesy of Gregory Fowler.

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary


No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

AIDS 2010
Choose a Topic:
Previous Conferences